JP2014521684A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014521684A5 JP2014521684A5 JP2014523441A JP2014523441A JP2014521684A5 JP 2014521684 A5 JP2014521684 A5 JP 2014521684A5 JP 2014523441 A JP2014523441 A JP 2014523441A JP 2014523441 A JP2014523441 A JP 2014523441A JP 2014521684 A5 JP2014521684 A5 JP 2014521684A5
- Authority
- JP
- Japan
- Prior art keywords
- growth hormone
- ctp
- polypeptide
- use according
- chorionic gonadotropin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000018997 Growth Hormone Human genes 0.000 claims 23
- 108010051696 Growth Hormone Proteins 0.000 claims 23
- 239000000122 growth hormone Substances 0.000 claims 23
- 229920001184 polypeptide Polymers 0.000 claims 11
- 229940015047 Chorionic Gonadotropin Drugs 0.000 claims 10
- 102000011022 Chorionic Gonadotropin Human genes 0.000 claims 10
- 108010062540 Chorionic Gonadotropin Proteins 0.000 claims 10
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 5
- 102000014429 Insulin-like growth factor Human genes 0.000 claims 4
- 108050003490 Insulin-like growth factor Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 230000001939 inductive effect Effects 0.000 claims 2
- 210000000577 Adipose Tissue Anatomy 0.000 claims 1
- 230000001225 therapeutic Effects 0.000 claims 1
- 230000004584 weight gain Effects 0.000 claims 1
- 235000019786 weight gain Nutrition 0.000 claims 1
- 230000004580 weight loss Effects 0.000 claims 1
Claims (18)
- 対象においてインスリン様成長因子（ＩＧＦ−１）レベルを正常な治療範囲内に維持するための薬剤の調製のための治療有効量のポリペプチドの使用であって、
前記ポリペプチドが、
成長ホルモンと、
前記成長ホルモンのアミノ末端に結合される１つの絨毛性ゴナドトロピンカルボキシ末端ペプチド（ＣＴＰ）と、
前記成長ホルモンのカルボキシ末端に結合される２つの絨毛性ゴナドトロピンＣＴＰとを含むことを特徴とする使用。 - ヒト対象においてインスリン様成長因子（ＩＧＦ−１）レベルを増加させるための薬剤の調製のための治療有効量のポリペプチドの使用であって、
前記ポリペプチドが、
成長ホルモンと、
前記成長ホルモンのアミノ末端に結合される１つの絨毛性ゴナドトロピンカルボキシ末端ペプチド（ＣＴＰ）と、
前記成長ホルモンのカルボキシ末端に結合される２つの絨毛性ゴナドトロピンＣＴＰとを含むことを特徴とする使用。 - ヒト対象において成長ホルモンの投薬頻度を減少させるための薬剤の調製のための治療有効量のポリペプチドの使用であって、
前記ポリペプチドが、
成長ホルモンと、
前記成長ホルモンのアミノ末端に結合される１つの絨毛性ゴナドトロピンカルボキシ末端ペプチド（ＣＴＰ）と、
前記成長ホルモンのカルボキシ末端に結合される２つの絨毛性ゴナドトロピンＣＴＰとを含むことを特徴とする使用。 - 小児または青年であるヒト対象において、成長または体重増加を誘発するための薬剤の調製のための治療有効量のポリペプチドの使用であって、
前記ポリペプチドが、
成長ホルモンと、
前記成長ホルモンのアミノ末端に結合される１つの絨毛性ゴナドトロピンカルボキシ末端ペプチド（ＣＴＰ）と、
前記成長ホルモンのカルボキシ末端に結合される２つの絨毛性ゴナドトロピンＣＴＰとを含むことを特徴とする使用。 - ヒト対象において体重減少を誘発するか、または体脂肪を減少させるための薬剤の調製のための治療有効量のポリペプチドの使用であって、
前記ポリペプチドが、
成長ホルモンと、
前記成長ホルモンのアミノ末端に結合される１つの絨毛性ゴナドトロピンカルボキシ末端ペプチド（ＣＴＰ）と、
前記成長ホルモンのカルボキシ末端に結合される２つの絨毛性ゴナドトロピンＣＴＰとを含むことを特徴とする使用。 - 少なくとも１つのＣＴＰが、グリコシル化されていることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 少なくとも１つのＣＴＰが、切り詰められていることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 少なくとも１つのＣＴＰが、リンカーを介して前記成長ホルモンに結合されていることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 前記リンカーが、ペプチド結合であることを特徴とする請求項８に記載の使用。
- 少なくとも１つのＣＴＰの配列が、配列番号１および配列番号２からなる群から選択されるアミノ酸配列によってコードされることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 前記ポリペプチドが、シグナルペプチドをさらに含むことを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 前記シグナルペプチドが、配列番号３に示されるアミノ酸配列を含むことを特徴とする請求項１１に記載の使用。
- 前記成長ホルモンが、１週間に１回または２週間に１回投与されることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 前記成長ホルモンが、０．０５〜７．２ｍｇ／投与の用量で投与されることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 前記成長ホルモンが、約２ｍｇ／投与の用量で投与されることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 前記成長ホルモンが、約４ｍｇ／投与の用量で投与されることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 前記成長ホルモンが、約１．２ｍｇ／投与の用量で投与されることを特徴とする請求項１〜５のいずれか１項に記載の使用。
- 前記成長ホルモンが、前記対象に皮下投与されることを特徴とする請求項１〜５のいずれか１項に記載の使用。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/195,931 | 2011-08-02 | ||
| US13/195,931 US8450269B2 (en) | 2006-02-03 | 2011-08-02 | Long-acting growth hormone and methods of producing same |
| PCT/IL2012/050288 WO2013018098A2 (en) | 2011-08-02 | 2012-08-02 | Long-acting growth hormone and methods of producing same |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014521684A JP2014521684A (ja) | 2014-08-28 |
| JP2014521684A5 true JP2014521684A5 (ja) | 2015-09-24 |
| JP6153930B2 JP6153930B2 (ja) | 2017-06-28 |
Family
ID=47629749
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014523441A Active JP6153930B2 (ja) | 2011-08-02 | 2012-08-02 | 持続型成長ホルモンおよびそれを生成する方法 |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8450269B2 (ja) |
| EP (2) | EP3482765B1 (ja) |
| JP (1) | JP6153930B2 (ja) |
| KR (3) | KR20210013300A (ja) |
| CN (2) | CN104010650A (ja) |
| AU (1) | AU2012291617B2 (ja) |
| BR (1) | BR112014002491A2 (ja) |
| CA (1) | CA2843672A1 (ja) |
| CL (2) | CL2014000254A1 (ja) |
| CO (1) | CO7020850A2 (ja) |
| DK (1) | DK2739298T3 (ja) |
| EA (2) | EA035352B1 (ja) |
| ES (1) | ES2706734T3 (ja) |
| HK (1) | HK1200349A1 (ja) |
| HU (1) | HUE042755T2 (ja) |
| MX (2) | MX360802B (ja) |
| PL (1) | PL2739298T4 (ja) |
| PT (1) | PT2739298T (ja) |
| SI (1) | SI2739298T1 (ja) |
| TR (1) | TR201821186T4 (ja) |
| WO (1) | WO2013018098A2 (ja) |
Families Citing this family (58)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| CN104487082A (zh) | 2012-04-19 | 2015-04-01 | 奥普科生物制品有限公司 | 长效胃泌酸调节素变体及其生产方法 |
| BR122020018510B1 (pt) | 2012-11-20 | 2023-03-14 | Opko Biologics Ltd | Método para aumentar incrementalmente o tamanho hidrodinâmico de um fator de coagulação ativado viia |
| WO2014159813A1 (en) | 2013-03-13 | 2014-10-02 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| CN103524626B (zh) * | 2013-09-27 | 2016-09-07 | 武汉龙科生物技术有限公司 | 重组双靶点蛋白药物及其应用 |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| DK3060239T3 (da) * | 2013-10-21 | 2020-08-03 | Opko Biologics Ltd | Langtidsvirkende polypeptider og fremgangsmåder til fremstilling og indgivelse heraf |
| ES2896971T3 (es) | 2014-11-21 | 2022-02-28 | Ascendis Pharma Endocrinology Div A/S | Formas de administración de hormona del crecimiento de acción prolongada |
| CN107438623B (zh) * | 2014-12-10 | 2023-07-14 | Opko生物科学有限公司 | 长效的ctp修饰的生长激素多肽的制备方法 |
| JP7000153B2 (ja) * | 2014-12-10 | 2022-01-19 | オプコ バイオロジクス リミテッド | 長時間作用性ｃｔｐ修飾成長ホルモンポリペプチドを生成する方法 |
| WO2016203482A2 (en) | 2015-06-19 | 2016-12-22 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| SG11201805026SA (en) | 2016-01-08 | 2018-07-30 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low npr-c binding |
| AU2017205273C1 (en) | 2016-01-08 | 2022-12-01 | Ascendis Pharma Growth Disorders A/S | Controlled-release CNP agonists with reduced side-effects |
| PL3400019T3 (pl) | 2016-01-08 | 2023-01-23 | Ascendis Pharma Growth Disorders A/S | Proleki cnp z przyłączeniem nośnika w ugrupowaniu pierścieniowy |
| NZ743488A (en) | 2016-01-08 | 2023-02-24 | Ascendis Pharma Growth Disorders As | Controlled-release cnp agonists with low initial npr-b activity |
| EP3400020A1 (en) | 2016-01-08 | 2018-11-14 | Ascendis Pharma Growth Disorders A/S | Cnp prodrugs with large carrier moieties |
| WO2017118700A1 (en) | 2016-01-08 | 2017-07-13 | Ascendis Pharma Growth Disorders A/S | Controlled-release cnp agonists with increased nep stability |
| EP3423103A1 (en) | 2016-03-01 | 2019-01-09 | Ascendis Pharma Bone Diseases A/S | Pth prodrugs |
| HUE064463T2 (hu) | 2016-07-11 | 2024-03-28 | Opko Biologics Ltd | Hosszantartó hatású VII. koagulációs faktor és az elõállítására vonatkozó eljárások |
| WO2018011266A1 (en) | 2016-07-13 | 2018-01-18 | Ascendis Pharma A/S | Conjugation method for carrier-linked prodrugs |
| JP7039574B2 (ja) | 2016-09-29 | 2022-03-22 | アセンディス ファーマ ボーン ディジージズ エー／エス | 放出制御ｐｔｈ化合物の漸増用量設定 |
| CN109789189B (zh) | 2016-09-29 | 2024-01-23 | 阿森迪斯药物骨疾病股份有限公司 | 控释pth化合物的剂量方案 |
| CN117257922A (zh) | 2016-09-29 | 2023-12-22 | 阿森迪斯药物骨疾病股份有限公司 | 具有低峰-谷比的pth化合物 |
| CN109843295B (zh) | 2016-09-29 | 2022-04-05 | 阿森迪斯药物生长障碍股份有限公司 | 控释cnp激动剂的组合疗法 |
| AU2019246389A1 (en) | 2018-03-28 | 2020-08-27 | Ascendis Pharma Oncology Division A/S | IL-2 conjugates |
| WO2019185706A1 (en) | 2018-03-28 | 2019-10-03 | Ascendis Pharma A/S | Conjugates |
| KR20210013584A (ko) | 2018-05-18 | 2021-02-04 | 아센디스 파마 본 디지즈 에이/에스 | Pth 접합체의 개시 용량 |
| CN108676096B (zh) * | 2018-05-22 | 2022-03-29 | 北京伟杰信生物科技有限公司 | 重组猪fsh-ctp融合蛋白及其制备方法与应用 |
| AU2019367647A1 (en) * | 2018-10-26 | 2021-06-03 | Ethadox Ltd. | Compositions and methods for biodegrading alcohol |
| US20220088149A1 (en) | 2019-02-11 | 2022-03-24 | Ascendis Pharma Bone Diseases A/S | Liquid Pharmaceutical Formulations of PTH Conjugates |
| EP3923906A1 (en) | 2019-02-11 | 2021-12-22 | Ascendis Pharma Growth Disorders A/S | Dry pharmaceutical formulations of cnp conjugates |
| US20220088147A1 (en) | 2019-03-04 | 2022-03-24 | Ascendis Pharma Endocrinology Division A/S | Long-acting growth hormone dosage forms with superior efficacy to daily somatropin |
| CA3143442A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma A/S | Conjugates of heteroaromatic nitrogen-comprising compounds |
| AU2020295721A1 (en) | 2019-06-21 | 2021-12-23 | Ascendis Pharma A/S | Conjugates of π-electron-pair-donating heteroaromatic nitrogen-comprising compounds |
| WO2020254602A1 (en) | 2019-06-21 | 2020-12-24 | Ascendis Pharma A/S | Conjugates of an electron-donating nitrogen or tertiary amine comprising compounds |
| JP2023512427A (ja) | 2020-01-03 | 2023-03-27 | アセンディス ファーマ エー／エス | 分子内転位を受けるコンジュゲート |
| WO2021144249A1 (en) | 2020-01-13 | 2021-07-22 | Ascendis Pharma Bone Diseases A/S | Hypoparathyroidism treatment |
| EP4161956A1 (en) | 2020-06-03 | 2023-04-12 | Ascendis Pharma Oncology Division A/S | Il-2 sequences and uses thereof |
| AU2021319863A1 (en) | 2020-08-05 | 2023-02-16 | Ascendis Pharma A/S | Conjugates comprising reversible linkers and uses thereof |
| JP2023540701A (ja) | 2020-08-28 | 2023-09-26 | アセンディス ファーマ オンコロジー ディヴィジョン エー／エス | グリコシル化ｉｌ－２タンパク質及びその使用 |
| IL301411A (en) | 2020-09-28 | 2023-05-01 | Ascendis Pharma Bone Diseases As | Improving the physical and mental condition of patients with hypoparathyroidism |
| CN112175964B (zh) * | 2020-10-23 | 2022-03-29 | 安徽中起生物科技有限公司 | 一种重组猪生长激素及其制备方法和应用 |
| KR20230164709A (ko) | 2021-04-01 | 2023-12-04 | 아센디스 파마 에이에스 | 염증 유발 질환을 치료하기 위한 지속형 성장 호르몬의 용도 |
| CN114010765A (zh) * | 2021-08-30 | 2022-02-08 | 上海延立药业有限公司 | 一种长效人生长激素 |
| AU2022350937A1 (en) | 2021-09-22 | 2024-03-21 | Ascendis Pharma Bone Diseases A/S | Long-acting pth compound treatments |
| WO2023110758A1 (en) | 2021-12-13 | 2023-06-22 | Ascendis Pharma Growth Disorders A/S | Effective doses of cnp conjugates |
| WO2023227505A1 (en) | 2022-05-23 | 2023-11-30 | Ascendis Pharma Growth Disorders A/S | Liquid pharmaceutical formulations of cnp compounds |
Family Cites Families (84)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| JPS5781447A (en) | 1980-11-11 | 1982-05-21 | Toyo Jozo Co Ltd | Human chorionic gonadotropic hormone c-terminal fragment |
| US4853332A (en) | 1982-10-19 | 1989-08-01 | Cetus Corporation | Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of biologically active proteins |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| DE3421468A1 (de) | 1984-06-08 | 1985-12-19 | Dr. Rentschler Arzneimittel Gmbh & Co, 7958 Laupheim | Lipidnanopellets als traegersystem fuer arzneimittel zur peroralen anwendung |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| DE122007000007I2 (de) | 1986-04-09 | 2010-12-30 | Genzyme Corp | Genetisch transformierte Tiere, die ein gewünschtes Protein in Milch absondern |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| US4873316A (en) | 1987-06-23 | 1989-10-10 | Biogen, Inc. | Isolation of exogenous recombinant proteins from the milk of transgenic mammals |
| WO1989010756A1 (en) | 1988-05-06 | 1989-11-16 | Toray Industries, Inc. | STABLE INTERFERON beta COMPOSITION |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| AU648020B2 (en) | 1989-02-21 | 1994-04-14 | Washington University | Modified forms of reproductive hormones |
| US6225449B1 (en) | 1991-10-04 | 2001-05-01 | Washington University | Hormone analogs with multiple CTP extensions |
| US5705478A (en) | 1989-02-21 | 1998-01-06 | Washington University | Covalently linked β subunits of the glycoprotein hormones as antagonists |
| US5338835A (en) | 1989-02-21 | 1994-08-16 | Washington University | CTP-extended form of FSH |
| US5792460A (en) | 1989-02-21 | 1998-08-11 | Washington University | Modified glycoprotein hormones having a CTP at the amino terminus |
| US5464764A (en) | 1989-08-22 | 1995-11-07 | University Of Utah Research Foundation | Positive-negative selection methods and vectors |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US7217689B1 (en) | 1989-10-13 | 2007-05-15 | Amgen Inc. | Glycosylation analogs of erythropoietin |
| US5126324A (en) | 1990-06-07 | 1992-06-30 | Genentech, Inc. | Method of enhancing growth in patients using combination therapy |
| US6028177A (en) | 1991-10-04 | 2000-02-22 | Washington University | Methods of detecting single-chain forms of the glycoprotein hormone quartet |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| ES2141229T3 (es) | 1993-04-20 | 2000-03-16 | Univ Washington | Productos farmaceuticos de proteinas y peptidos modificados. |
| US6737515B2 (en) | 1993-11-19 | 2004-05-18 | Washington University | Follicle stimulating hormone-glycosylation analogs |
| US6238890B1 (en) | 1994-02-18 | 2001-05-29 | Washington University | Single chain forms of the glycoprotein hormone quartet |
| US5935924A (en) | 1994-04-15 | 1999-08-10 | Genentech, Inc. | Treatment of congestive heart failure |
| US5541110A (en) | 1994-05-17 | 1996-07-30 | Bristol-Myers Squibb | Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica |
| BR9506313A (pt) | 1994-08-12 | 1997-08-05 | Univ Washington | Formas de cadeia simples do quarteto de hormônio de glicoproteína |
| US6083725A (en) | 1996-09-13 | 2000-07-04 | Transkaryotic Therapies, Inc. | Tranfected human cells expressing human α-galactosidase A protein |
| IL122732A0 (en) * | 1997-01-15 | 1998-08-16 | Akzo Nobel Nv | Liquid gonadotropin-containing formulation its preparation and a device containing same |
| US6310183B1 (en) | 1997-09-10 | 2001-10-30 | Novo Nordisk A/S | Coagulation factor VIIa composition |
| US6103501A (en) | 1997-11-17 | 2000-08-15 | Washington University | Single chain glycoprotein hormones comprising two β and one α subunits and recombinant production thereof |
| PL200586B1 (pl) | 1998-10-16 | 2009-01-30 | Biogen Idec Inc | Polipeptydy zawierające mutanty interferonu-beta-1a, kodujące je cząsteczki kwasów nukleinowych, komórki gospodarza transformowane tymi cząsteczkami, sposób wytwarzania polipeptydów, zawierające je kompozycje farmaceutyczne i zastosowania polipeptydów |
| US6514729B1 (en) | 1999-05-12 | 2003-02-04 | Xencor, Inc. | Recombinant interferon-beta muteins |
| PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| US20020127652A1 (en) | 2000-02-11 | 2002-09-12 | Schambye Hans Thalsgard | Follicle stimulating hormones |
| US7094566B2 (en) | 2000-03-16 | 2006-08-22 | Amgen Inc., | IL-17 receptor like molecules and uses thereof |
| JP4409135B2 (ja) | 2000-12-01 | 2010-02-03 | 武田薬品工業株式会社 | 生理活性物質含有製剤の製造法 |
| EP1346722B1 (en) | 2000-12-01 | 2008-12-10 | Takeda Pharmaceutical Company Limited | Method for producing preparation containing bioactive substance |
| WO2002046227A2 (en) | 2000-12-07 | 2002-06-13 | Eli Lilly And Company | Glp-1 fusion proteins |
| EP1342730B1 (en) | 2000-12-11 | 2006-03-15 | Cheil Jedang Corporation | Fusion protein having the enhanced in vivo activity of erythropoietin |
| KR101229995B1 (ko) | 2000-12-11 | 2013-02-06 | 씨제이 주식회사 | 생체내 에리스로포이에틴 활성이 증진된 융합단백질 |
| JP5160005B2 (ja) | 2000-12-28 | 2013-03-13 | 武田薬品工業株式会社 | 徐放性製剤 |
| EP1356809A4 (en) | 2000-12-28 | 2008-05-14 | Takeda Pharmaceutical | SUSTAINED RELEASE PREPARATIONS |
| US6887462B2 (en) | 2001-04-09 | 2005-05-03 | Chiron Corporation | HSA-free formulations of interferon-beta |
| US6824769B2 (en) | 2001-08-28 | 2004-11-30 | Vertex Pharmaceuticals Incorporated | Optimal compositions and methods thereof for treating HCV infections |
| GB0121709D0 (en) | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| US7081446B2 (en) | 2002-01-31 | 2006-07-25 | The Trustees Of Columbia University In The City Of New York | Long-acting follicle stimulating hormone analogues and uses thereof |
| US7173113B2 (en) | 2002-01-31 | 2007-02-06 | The Trustees Of Columbia University In The City Of New York | Long-acting hormone and growth factor compositions and uses thereof |
| US7459435B2 (en) | 2002-08-29 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| US7459436B2 (en) | 2002-11-22 | 2008-12-02 | Hoffmann-La Roche Inc. | Treatment of disturbances of iron distribution |
| JP4683319B2 (ja) | 2003-02-19 | 2011-05-18 | 武田薬品工業株式会社 | 徐放性製剤用の分散剤 |
| EP1595549A4 (en) | 2003-02-19 | 2010-09-22 | Takeda Pharmaceutical | DISPERSING AGENT FOR SUSTAINED RELEASE PREPARATIONS |
| CN1243022C (zh) * | 2003-10-17 | 2006-02-22 | 华东师范大学 | 生物修饰重组人生长激素复合物及其制备方法 |
| US7649084B2 (en) | 2003-11-12 | 2010-01-19 | University Of Georgia Research Foundation, Inc. | Recombinant glycoproteins related to feline thyrotropin |
| SI1696947T1 (sl) | 2003-12-19 | 2014-05-30 | F. Hoffmann-La Roche Ag | Uporaba eritropoetina pri zdravljenju motenj porazdelitve železa pri kroničnih vnetnih črevesnih boleznih |
| ATE489105T1 (de) | 2004-03-19 | 2010-12-15 | Baxter Int | Faktor ixa zur behandlung von blutungsstörungen |
| DE602005021509D1 (de) | 2004-08-17 | 2010-07-08 | Csl Behring Gmbh | Modifizierte vitamin-k-abhängige polypeptide |
| US8420602B2 (en) * | 2004-09-14 | 2013-04-16 | Landon C. G. Miller | Endocannabinoid conjugate and a pharmaceutical composition for treatment of neuronal disorders |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| US8476234B2 (en) | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US8304386B2 (en) | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| KR100900784B1 (ko) * | 2007-01-03 | 2009-06-02 | 주식회사 하이닉스반도체 | 반도체메모리소자 |
| WO2009114959A1 (zh) * | 2008-03-20 | 2009-09-24 | 中国人民解放军军事医学科学院毒物药物研究所 | 可注射用缓释药物制剂及其制备方法 |
-
2011
- 2011-08-02 US US13/195,931 patent/US8450269B2/en active Active
-
2012
- 2012-08-02 SI SI201231498T patent/SI2739298T1/sl unknown
- 2012-08-02 CN CN201280048492.0A patent/CN104010650A/zh active Pending
- 2012-08-02 AU AU2012291617A patent/AU2012291617B2/en active Active
- 2012-08-02 CN CN201710103795.2A patent/CN107080835A/zh active Pending
- 2012-08-02 WO PCT/IL2012/050288 patent/WO2013018098A2/en active Application Filing
- 2012-08-02 JP JP2014523441A patent/JP6153930B2/ja active Active
- 2012-08-02 MX MX2014001335A patent/MX360802B/es active IP Right Grant
- 2012-08-02 KR KR1020217002411A patent/KR20210013300A/ko not_active Application Discontinuation
- 2012-08-02 EP EP18198355.2A patent/EP3482765B1/en active Active
- 2012-08-02 BR BR112014002491A patent/BR112014002491A2/pt not_active Application Discontinuation
- 2012-08-02 KR KR1020147005420A patent/KR102028524B1/ko active IP Right Grant
- 2012-08-02 PL PL12819794T patent/PL2739298T4/pl unknown
- 2012-08-02 PT PT12819794T patent/PT2739298T/pt unknown
- 2012-08-02 DK DK12819794.4T patent/DK2739298T3/en active
- 2012-08-02 HU HUE12819794A patent/HUE042755T2/hu unknown
- 2012-08-02 KR KR1020197028467A patent/KR20190116526A/ko active Application Filing
- 2012-08-02 EP EP12819794.4A patent/EP2739298B1/en active Active
- 2012-08-02 EA EA201490393A patent/EA035352B1/ru unknown
- 2012-08-02 ES ES12819794T patent/ES2706734T3/es active Active
- 2012-08-02 EA EA202090577A patent/EA202090577A3/ru unknown
- 2012-08-02 TR TR2018/21186T patent/TR201821186T4/tr unknown
- 2012-08-02 CA CA2843672A patent/CA2843672A1/en active Pending
-
2014
- 2014-01-31 MX MX2018014072A patent/MX2018014072A/es unknown
- 2014-01-31 CL CL2014000254A patent/CL2014000254A1/es unknown
- 2014-02-12 CO CO14029693A patent/CO7020850A2/es unknown
-
2015
- 2015-01-28 HK HK15100967.2A patent/HK1200349A1/xx unknown
-
2020
- 2020-07-31 CL CL2020002010A patent/CL2020002010A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2014521684A5 (ja) | ||
| JP2009292810A5 (ja) | ||
| JP2010500399A5 (ja) | ||
| JP2008535800A5 (ja) | ||
| JP2016512213A5 (ja) | ||
| JP2008530245A5 (ja) | ||
| JP2016511752A5 (ja) | ||
| JP2010515686A5 (ja) | ||
| JP2012529296A5 (ja) | ||
| JP2011524420A5 (ja) | ||
| CN104023784A (zh) | 供持续释放的活性剂制剂 | |
| HRP20140616T1 (hr) | Peptidni analog oksintomodulina | |
| JP2014526254A5 (ja) | ||
| JP2015517489A5 (ja) | ||
| JP2009515529A5 (ja) | ||
| JP2017531613A5 (ja) | ||
| JP2016516016A5 (ja) | ||
| CA2965560A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| JP2016514132A5 (ja) | ||
| JP2010043001A (ja) | Ｇｌｐ−１誘導体とその用途 | |
| WO2010111617A4 (en) | Parathyroid hormone peptides and parathyroid hormone-related protein peptides and methods of use | |
| JP2013510169A5 (ja) | ||
| JP2011528334A5 (ja) | ||
| HRP20201114T1 (hr) | Dugodjelujući polipeptidi i postupci njihove proizvodnje i primjene | |
| JP2008531463A5 (ja) |